SIETES :: 92381 citas

Resultados de la búsqueda por MEDIOS DIAGNÓSTICOS REFINAR BÚSQUEDA

1.

Wise J. New test for asthma will save NHS millions, says NICE. BMJ 2017;359:j5540. [Ref.ID 102178]

2.

Anónimo. Riesgo de formación de depósitos cerebrales asociado a la administración de agentes de contraste con gadolinio: actualización de la información. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:1-2. [Ref.ID 102152]

3.

Öngür D. Dopamine dysfunction in schizophrenia and bipolar disorder - Never the twain shall meet?. JAMA Psychiatry 2017:11 de octubre. [Ref.ID 102090]

4.

Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, Turkheimer F, McGuire P, Young AH, Howes OD. A tests of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry 2017:11 de octubre. [Ref.ID 102089]

5.

Vliegenthart ADB, Berends C, Potter CMJ, Kersaudy-Kerhoas M, Dear JW. MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol 2017;83:2027-33. [Ref.ID 102028]

6.

Young LA, Buse JB, Weaver MA, Vu MB, Mitchell M, Blakeney T, Grimm K, Rees J, Niblock F, Donahue KE, for the Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings. A randomized trial. JAMA Intern Med 2017;177:920-9. [Ref.ID 102017]

7.

Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

8.

Anónimo. Riesgo de formación de depósitos cerebrales asociado a la administración de agentes de contraste con gadolinio. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:1-3. [Ref.ID 101459]

9.

Anónimo. FDA approves rucaparib to treat patients with ovarian cancer whose tumors have BRCA mutation. DIA Daily 2016:1. [Ref.ID 101001]

10.

Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 2016;375:1438-47. [Ref.ID 100802]

11.

Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, Oh SP, Olitsky SE, Pyeritz RE, Gossage JR. Effect of topical intranasal therapy on epistaxis frequency in patients with heraditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA 2016;316:943-51. [Ref.ID 100742]

12.

Anónimo. Verily, Sanofi unveil diabetes joint venture. DIA Daily 2016:1. [Ref.ID 100656]

13.

Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A. Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 2016;316:96-8. [Ref.ID 100620]

14.

Schroeder LF, Guarner J, Eibireer A, Castle PE, Amukele TK. Time for a model list of essential diagnostics. N Engl J Med 2016;374:2511-4. [Ref.ID 100451]

15.

Anónimo. Metformin-containing drugs: drug safety communication - Revised warnings for certain patients with reduced kidney function. FDA U.S. Food and Drug Administration 2016:8 de abril. [Ref.ID 100111]

16.

Elmore JG, Nelson HD, Pepe MS, Longton GM, Tosteson ANA, Geller B, Onega T, Carney PA, Jackson SL, Allison KH, Weaver DL. Variability in pathologists' interpretations of individual breast biopsy slides: a population perspective. Ann Intern Med 2016;164:649-55. [Ref.ID 100080]

17.

Cohen D. Rivaroxaban: can we trust the evidence?. BMJ 2016;352:i575. [Ref.ID 100048]

18.

Dyer O. Senior citizens were routinely tested for “angel dust” in scam that led to $256m settlement. BMJ 2015;351:h5743. [Ref.ID 99638]

19.

Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]

20.

Anónimo. FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). FDA U.S. Food and Drug Administration 2015:27 de julio. [Ref.ID 99269]